FEMASYS INC (FEMY) Stock Price, Quote, News and Overview
NASDAQ:FEMY - Nasdaq - US31447E1055 - Common Stock - Currency: USD
FEMY Quote, Performance and Key Statistics
1.04
-0.02 (-1.89%)
The current stock price of FEMY is 1.04 USD. In the past month the price decreased by -15.45%. In the past year, price decreased by -18.75%.
FEMY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.47 | 227.72B | ||
| ISRG | INTUITIVE SURGICAL INC | 70.62 | 193.38B | ||
| BSX | BOSTON SCIENTIFIC CORP | 38.7 | 154.56B | ||
| SYK | STRYKER CORP | 30.06 | 143.75B | ||
| MDT | MEDTRONIC PLC | 14.67 | 103.48B | ||
| BDX | BECTON DICKINSON AND CO | 12.16 | 49.21B | ||
| EW | EDWARDS LIFESCIENCES CORP | 28.84 | 44.09B | ||
| IDXX | IDEXX LABORATORIES INC | 44 | 40.65B | ||
| RMD | RESMED INC | 26.74 | 35.61B | ||
| DXCM | DEXCOM INC | 51.22 | 33.14B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.03 | 31.66B | ||
| STE | STERIS PLC | 26.02 | 23.87B |
Related stock screener links
About FEMY
Company Profile
Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company is headquartered in Suwanee, Georgia and currently employs 69 full-time employees. The company went IPO on 2021-06-18. The firm is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The firm has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The company also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Company Info
FEMASYS INC
3950 Johns Creek Court, Suite 100
Suwanee GEORGIA US
CEO: Kathy Lee-Sepsick
Employees: 33
Phone: 17705003910
FEMASYS INC / FEMY FAQ
What is the stock price of FEMASYS INC today?
The current stock price of FEMY is 1.04 USD. The price decreased by -1.89% in the last trading session.
What is the ticker symbol for FEMASYS INC stock?
The exchange symbol of FEMASYS INC is FEMY and it is listed on the Nasdaq exchange.
On which exchange is FEMY stock listed?
FEMY stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for FEMASYS INC stock?
10 analysts have analysed FEMY and the average price target is 8.84 USD. This implies a price increase of 750% is expected in the next year compared to the current price of 1.04. Check the FEMASYS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is FEMASYS INC worth?
FEMASYS INC (FEMY) has a market capitalization of 28.33M USD. This makes FEMY a Nano Cap stock.
How many employees does FEMASYS INC have?
FEMASYS INC (FEMY) currently has 33 employees.
What are the support and resistance levels for FEMASYS INC (FEMY) stock?
FEMASYS INC (FEMY) has a resistance level at 1.1. Check the full technical report for a detailed analysis of FEMY support and resistance levels.
Is FEMASYS INC (FEMY) expected to grow?
The Revenue of FEMASYS INC (FEMY) is expected to grow by 222.54% in the next year. Check the estimates tab for more information on the FEMY EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy FEMASYS INC (FEMY) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FEMY, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FEMY, evaluating the profitability, health, valuation and growth aspects
- FEMASYS INC (FEMY) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- FEMASYS INC (FEMY) Sales and EPS estimates to see what analysts future expectations are.
- FEMASYS INC (FEMY) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- FEMASYS INC (FEMY) Insider and Institutional Ownership to learn about the owners and their transactions.
- FEMASYS INC (FEMY) Stock Chart to make your own analysis
- FEMASYS INC (FEMY) Latest news and press-releases to stay up to date.
Does FEMASYS INC (FEMY) stock pay dividends?
FEMY does not pay a dividend.
What is the Price/Earnings (PE) ratio of FEMASYS INC (FEMY)?
FEMASYS INC (FEMY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.91).
What is the Short Interest ratio of FEMASYS INC (FEMY) stock?
The outstanding short interest for FEMASYS INC (FEMY) is 3.95% of its float. Check the ownership tab for more information on the FEMY short interest.
FEMY Technical Analysis
FEMY Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FEMY. FEMY has a bad profitability rating. Also its financial health evaluation is rather negative.
FEMY Financial Highlights
Over the last trailing twelve months FEMY reported a non-GAAP Earnings per Share(EPS) of -0.91. The EPS decreased by -8.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -159.02% | ||
| ROE | -1057.44% | ||
| Debt/Equity | 2.89 |
FEMY Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to FEMY. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 30% and a revenue growth 222.54% for FEMY